Treatment interruptions to decrease risk of resistance emerging during therapy switching in HIV treatment

Proceedings of the IEEE Conference on Decision and Control

Volumn , Issue , 2007, Pages 5174-5179

  Zurakowski, Ryan ^a   Wodarz, Dominik ^b  

^a UNIVERSITY OF DELAWARE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; DRUG PRODUCTS; HEALTH RISKS;

RESISTANT STRAINS;

PATIENT TREATMENT;

EID: 62749130537     PISSN: 07431546     EISSN: 25762370     Source Type: Conference Proceeding    
DOI: 10.1109/CDC.2007.4434887     Document Type: Conference Paper

References (17)

1. D. Ho, A. Neumann, A. Perelson, W. Chen, J. Leonard, and M. Markowitz, "Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection." Nature, vol. 373, no. 6510, pp. 123-6, Jan 1995.
2. S. Bonhoeffer and M. Nowak, "Pre-existence and emergence of drug resistance in HIV-1 infection." Proc R Soc Lond B Biol Sci, vol. 264, no. 1382, pp. 631-7, May 1997.
3. R. Ribeiro and S. Bonhoeffer, "Production of resistant HIV mutants during antiretroviral therapy." Proc Natl Acad Sci USA, vol. 97, no. 14, pp. 7681-6, Jul 2000.
4. S. M. Hammer, M. S. Saag, M. Schechter, J. S. G. Montaner, R. T. Schooley, D. M. Jacobsen, M. A. Thompson, C. C. J. Carpenter, M. A. Fischl, B. G. Gazzard, J. M. Gatell, M. S. Hirsch, D. A. Katzenstein, D. D. Richman, S. Vella, P. G. Yeni, P. A. Volberding, and I. A. S.-U. Panel, "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel." Top HIV Med, vol. 14, no. 3, pp. 827-843, 2006.
5. J. Ananworanich, R. Nuesch, M. L. Braz, P. Chetchotisakd, A. Vibhagool, S. Wicharuk, K. Ruxrungtham, H. Furrer, D. Cooper, B. Hirschel, E. Bernasconi, M. Cavassini, C. Ebnther, C. Fagard, D. Genn, N. Khanna, L. Perrin, P. Phanupak, S. Ubolyam, P. Vernazza, S. Yerly, and S. H. C. Study, "Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial." AIDS, vol. 17, no. 15, pp. F33-7, Oct 2003.
6. J. Ananworanich, A. Gayet-Ageron, M. L. Braz, W. Prasithsirikul, P. Chetchotisakd, S. Kiertiburanakul, W. Munsakul, P. Raksakulkarn, S. Tansuphasawasdikul, S. Sirivichayakul, M. Cavassini, U. Karrer, D. Genn, R. Nesch, P. Vernazza, E. Bernasconi, D. Leduc, C. Satchell, S. Yerly, L. Perrin, A. Hill, T. Perneger, P. Phanuphak, H. Furrer, D. Cooper, K. Ruxrungtham, B. Hirschel, S. S. Group, and S. H. C. Study, "CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial." Lancet, vol. 368, no. 9534, pp. 459-465, Aug 2006.
7. C. A. Benson, F. Vaida, D. V Havlir, G. F. Downey, M. M. Lederman, R. M. Gulick, M. J. Glesby, M. Wantman, C. J. Bixby, A. R. Rinehart, S. Snyder, R. Wang, S. Patel, J. W. Mellors, and A. C. T G. A. S. Team, "A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologie results of ACTG A5086." J Infect Dis, vol. 194, no. 9, pp. 1309-1318, Nov 2006.
8. S. G. Deeks, R. Hoh, T. B. Neilands, T. Liegler, F. Aweeka, C. J. Petropoulos, R. M. Grant, and J. N. Martin, "Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection." J Infect Dis, vol. 192, no. 9, pp. 1537-1544, Nov 2005. [Online]. Available: http://dx.doi.org/10.1086/496892
9. J. Ghosn, M. Wirden, N. Ktorza, G. Peytavin, H. At-Mohand, L. Schneider, S. Dominguez, F. Bricaire, V. Calvez, D. Costagliola, and C. Katlama, "No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients." AIDS, vol. 19, no. 15, pp. 1643-1647, Oct 2005.
10. C. Katlama, S. Dominguez, K. Gourlain, C. Duvivier, C. Delaugerre, M. Legrand, R. Tubiana, J. Reynes, J.-M. Molina, G. Peytavin, V. Calvez, and D. Costagliola, "Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)." AIDS, vol. 18, no. 2, pp. 217-226, Jan 2004.
11. J. Lawrence, D. L. Mayers, K. H. Hullsiek, G. Collins, D. I. Abrams, R. B. Reisler, L. R. Crane, B. S. Schmetter, T. J. Dionne, J. M. Saldanha, M. C. Jones, J. D. Baxter, and . S. T. of the Terry Beim Community Programs for Clinical Research on AIDS, "Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus." N Engl J Med, vol. 349, no. 9, pp. 837-846, Aug 2003.
12. J. Martinez-Picado, E. Negredo, L. Ruiz, A. Shintani, C. R. Fumaz, C. Zala, P. Domingo, J. Vilar, J. M. Llibre, P. Viciana, K. Hertogs, C. Boucher, R. T. D'Aquila, B. Clotet, and S. W. A. T. C. H. S. Team, "Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial." Ann Intern Med, vol. 139, no. 2, pp. 81-89, Jul 2003.
13. R. M. D'Amato, R. T. D'Aquila, and L. M. Wein, "Management of antiretroviral therapy for HIV infection: modelling when to change therapy." Antivir Ther, vol. 3, no. 3, pp. 147-158, 1998.
14. M. A. Nowak, S. Bonhoeffer, G. M. Shaw, and R. M. May, "Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations." J Theor Biol, vol. 184, no. 2, pp. 203-217, Jan 1997. [Online]. Available: http://dx.doi.org/10.1006/jtbi.1996.0307
15. C. Gray, J. Lawrence, E. Ranheim, M. Vierra, M. Zupancic, M. Winters, J. Altman, J. Montoya, A. Zolopa, J. Schapiro, A. Haase, and T. Merigan, "Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells." AIDS Res Hum Retroviruses, vol. 16, no. 14, pp. 1357-69, Sep 2000. [Online]. Available: http://dx.doi.org/10.1089/ 08892220050140900
16. F. Aiuti and I. Mezzaroma, "Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART." AIDS Rev, vol. 8, no. 2, pp. 88-97, 2006.
17. D. Finzi, J. Blankson, J. Siliciano, J. Margolick, K. Chadwick, T. Pierson, K. Smith, J. Lisziewicz, F. Lori, C. Flexner, T. Quinn, R. Chaisson, E. Rosenberg, B. Walker, S. Gange, J. Gallant, and R. Siliciano, "Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy." Nat Med, vol. 5, no. 5, pp. 512-7, May 1999.